Considerations For ADT Selection And Patient Education on Treatment-Related AEs

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

EP: 1.Cardiovascular Disease Risk in Men with Prostate Cancer

EP: 2.Examining the Data From Key Clinical Trials, and Practical Strategies

EP: 3.Strategies for Mitigating Cardiovascular Risk

EP: 4.Summary and Case Study

EP: 5.A Medical Oncologist Reflects on a Typical Prostate Cancer Patient

EP: 6.A Urologist Reflects on a Typical Prostate Cancer Patient

EP: 7.A Cardiologist Reflects on a Typical Prostate Cancer Patient

EP: 8.Practice-Related And Provider-Patient Communication Strategies For Prostate Cancer Care

EP: 9.A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 10.A Medical Oncologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 11.Typical Examinations And Tests For Cardiovascular Risk Assessment in a Cardiology Practice

EP: 12.Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice

EP: 13.A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation

EP: 14.A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation

EP: 15.Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

Now Viewing

EP: 16.Considerations For ADT Selection And Patient Education on Treatment-Related AEs

EP: 17.A Urologist’s Approach to Followup For Patients on ADT And Practice Communication Strategies

EP: 18.A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

EP: 19.A Urologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

EP: 20.A Cardiologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

January 2023 AbbVie Inc. Company Confidential

Related Videos

Related Content

Advertisement

July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick

Here’s a look back at notable news between April and June 2025.

July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke

The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.

Related Content

Advertisement

July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick

Here’s a look back at notable news between April and June 2025.

July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke

The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.